Alarmins: awaiting a clinical response - PubMed (original) (raw)

Review

. 2012 Aug;122(8):2711-9.

doi: 10.1172/JCI62423. Epub 2012 Aug 1.

Affiliations

Review

Alarmins: awaiting a clinical response

James K Chan et al. J Clin Invest. 2012 Aug.

Abstract

Alarmins are endogenous molecules that are constitutively available and released upon tissue damage and activate the immune system. Current evidence indicates that uncontrolled and excessive release of alarmins contributes to the dysregulated processes seen in many inflammatory and autoimmune conditions, as well as tumorigenesis and cancer spread. Conversely, alarmins have also been found to play a major role in the orchestration of tissue homeostasis, including repair and remodeling in the heart, skin, and nervous system. Here, we provide an update and overview on alarmins, highlighting the areas that may benefit from this clinical translation.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Alarmin pathway as potential therapeutic target in the innate inflammatory cascade.

The upstream alarmin signaling pathways are potential therapeutic targets for immunomodulation in both acute and chronic inflammatory diseases. This has been achieved in animal models by directly targeting the alarmins using antibodies or competitive inhibitors, e.g., Box A (HMGB1), or by targeting the pattern recognition receptors (PRR) with antibodies or soluble decoy receptors. The convergence of S100 proteins and HMGB1 onto their receptors may be a rate-limiting step in this pathway and hence represents an attractive therapeutic target. Downstream cytokine blockade, including of TNF-α and IL-6, is used clinically in the treatment of chronic inflammatory diseases such as RA and inflammatory bowel disease, but remains ineffective in a significant proportion of patients. Cytokine blockade has been notably unsuccessful in patients with acute inflammatory disorders.

Figure 2

Figure 2. Induction of chronic and autoimmune inflammation by alarmins by upregulating the adaptive immune response.

Alarmins recruit immature DCs and induce their functional maturation, leading them to take up antigens and home to secondary lymphoid organs. Here, they present antigenic epitopes to naive T cells, driving Th1 T cell polarization and inducing an adaptive immune response. Persistent release of alarmins upregulates ectopic MHC type I and II expression and presentation of previously unencountered antigens as well as uncontrolled proliferation of T cells, driving a hyper-inflammatory environment. Adapted with permission from Immunological Reviews (7).

Similar articles

Cited by

References

    1. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17(4):359–365. doi: 10.1016/j.coi.2005.06.002. - DOI - PubMed
    1. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science. 2009;323(5922):1683–1684. doi: 10.1126/science.1172794. - DOI - PubMed
    1. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305. doi: 10.1126/science.1071059. - DOI - PubMed
    1. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–566. doi: 10.1189/jlb.1008647. - DOI - PubMed
    1. Zhu S, Li W, Ward MF, Sama AE, Wang H. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets. 2010;9(1):60–72. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources